Amgen Inc (AMGN) received encouraging news from the FDA as the regulatory body granted priority review status to the New Drug Application (NDA) for its pipeline candidate, ivabradine. Amgen is looking to get ivabradine approved for the treatment of chronic heart failure. Te FDA grants priority review status to candidates which have the potential to bring significant improvements in terms of safety or effectiveness in … Continue reading Biotech Stock News: Amgen Set for Big Things in the Near Future

United Therapeutics Corporation (UTHR) shares surged approximately 28.5% after the company announced that the U.S. District Court for the District of New Jersey has rendered a favorable decision in the Remodulin patent infringement lawsuit against Sandoz, the generic division of Novartis (NVS). As per the court’s ruling, Sandoz will not be able to launch its generic version of Remodulin until patent no. 6,765,117 protecting Remodulin … Continue reading Biotech News: United Therapeutics Remains Strong Due to a Patent Case Win

The biotech sector had a strong run last week thanks mostly to Roche’s agreement to acquire InterMune (ITMN) for a hefty $8.3 billion. The announcement of this deal resulted in a spike in the share price of quite a few mid-cap biotech companies that are considered to be lucrative acquisition targets. The week’s most important news was the $8.3 billion agreement announced by Roche for … Continue reading Great Biotech Stocks Weekly Roundup

Biotech is back. This spring, biotech stocks collapsed. The Nasdaq Biotechnology Index tumbled 22% in about six weeks, inflicting huge losses on hedge funds and other investors, including holders of a popular exchange-traded fund known for its ticker “IBB,” the iShares Nasdaq Biotechnology ETF , which has about $5.5 billion in assets. So far in August, the Nasdaq Biotechnology Index is up 10%. That puts … Continue reading Biotech Stocks Back Up High : Analysis

Regado Biosciences, Inc (RGDO) announced that it is permanently terminating the enrollment process for its phase III REGULATE-PCI study on Revolixys Kit. Regado’s shares tumbled over 60% on the news. Regado was dealt a severe blow with the Data and Safety Monitoring Board for a late-stage study recommending the permanent termination of patient enrolment. The phase III study was a part of the company’s lead … Continue reading Biotech News: Regado Slumps Low Due to Poor Test Results

In a move which can have a lasting impact in the biotech segment of the stocks market, Bristol-Myers Squibb Company (BMY) entered into a collaboration with Celgene Corporation (CELG) to asses the safety, tolerability and preliminary efficacy of a cocktail therapy including its high potential immuno-oncology drug Opdivo (nivolumab, a PD-1 immune checkpoint inhibitor) and Celgene’s oncology treatment Abraxane in a phase I study. The … Continue reading Biotech Stock News: Bristol-Myers Partner Celgene for Oncology Treatments